Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
SLS, IBRX Stocks Surge on Eli Lilly's $2.875B Merida Deal
- Investors may watch and for continued momentum following Eli Lilly's acquisition announcement, as the deal indicates a potential 'M&A rampage' by large pharma. - The substantial valuation Eli Lilly placed on Merida, despite its early-stage pipeline, could serve as a catalyst for other biotech firms with promising immunology assets.
Based on reporting from yahoo-tickers-tape-movers.
Biotech stocks $SLS+WL and $IBRX+WL posted significant August gains, fueled by Eli Lilly's $2.875 billion acquisition of Merida. The deal suggests Big Pharma's ongoing willingness to invest heavily in novel immunology assets, potentially sparking further M&A activity in the sector.
Market context for this story
As of: After HoursLoading quotes…
Informational only — not investment advice. Full markets →
$IBRX
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
$SLS
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView charts — search any symbol in the widget. Confirm on /markets/IBRX and related $SLS, $XBI, $LLY. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
**Implied Volatility / Movement:** Normal
Biotech shares $SLS+WL and $IBRX+WL entered September following robust August performance, buoyed by Eli Lilly's substantial acquisition of Merida. The $2.875 billion deal for Merida, which has a lead candidate in Phase 1, signals a strong appetite among large pharmaceutical companies for innovative immunology platforms, potentially triggering a wave of mergers and acquisitions across the sector.
SLS shares experienced a 41% increase in August, while IBRX saw a 14% rise. Investors are scrutinizing the Merida deal valuation as a benchmark for other companies with similar therapeutic focuses. The sentiment among retail traders on platforms like Stocktwits for both SLS and IBRX was neutral, though discussion volume was notably high for SLS.
Eli Lilly's acquisition strategy is further evidenced by its prior deals, including the $1.2 billion purchase of Ventyx Biosciences and an agreement to acquire Orna Therapeutics for up to $2.4 billion. These moves collectively expand Lilly's capabilities in inflammasome inhibition and other advanced therapeutic areas.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
- Investors may watch and for continued momentum following Eli Lilly's a
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: September 1, 2026 at 3:00 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
Biotech M&A
A giant drug company spent billions to buy a smaller biotech firm, which got investors excited that other small biotech companies might also get bought out. People who own stocks like SLS and IBRX are hoping their companies could be next.
What changed
Eli Lilly's multi-billion dollar acquisition of early-stage biotech Merida revived buyout optimism across the immunology sector.
Who wins / who loses
Small-cap biotech firms with promising immunology pipelines benefit from buyout speculation, while investors face high volatility if future deals disappoint.
Time horizon
Think in terms of the next few weeks.
Confidence & best fit
medium confidence · Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $LLYBuild slowly — only if it fits your plan
Eli Lilly is the big company driving the trend by spending billions on new drugs.
View $LLY chart → · End-of-day delayed data
- $SLSWatch — track, don’t rush
This small drug stock jumped a lot recently because traders think it might be bought out next.
View $SLS chart → · End-of-day delayed data
Peer
- $IBRXWatch — track, don’t rush
Another small drug company that rose in sympathy when the big buyout news hit.
View $IBRX chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: volatile · Style: Bullish defined-risk call idea · Level: intermediate
Beginners should skip options here because small drug stocks can swing wildly up or down based on sudden news.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Monitor clinical trial catalyst calendars for small-cap biotechs in the immunology space.
What would break this thesis
- Macro tightening dries up venture and pharma capital for early-stage pipelines.
- Subsequent biotech buyout valuations drop significantly below the Merida benchmark.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).